) is scheduled to report first quarter 2014 results before the
opening bell on May 5. Last quarter, Pfizer had posted an
earnings surprise of 5.66%. Let's see how things are shaping up
for this announcement.
Factors at Play
Pfizer has delivered positive earnings surprises in the last
three quarters with an average beat of 4.31%.
Although revenues will continue to be impacted by the loss of
exclusivity of Lipitor as well as the expiration of a few
co-promotion agreements, products like Celebrex, Inlyta, Xalkori,
Xeljanz and Eliquis should continue to perform well. Lyrica,
which has billion-dollar potential, will remain the key growth
Meanwhile, cost cutting efforts and share buybacks should boost
the bottom line.
Our proven model does not conclusively show that Pfizer is likely
to beat earnings this quarter. That is because a stock needs to
have both a positive
(Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for
this to happen. That is not the case here as you will see below.
The Earnings ESP for Pfizer is -1.82% since the Most Accurate
estimate is $0.54 while the Zacks Consensus Estimate is $0.55.
Zacks #4 Rank (Sell):
Pfizer's Zacks Rank #4 (Sell) has little effect on the predictive
power of ESP because the Zacks Rank #4 when combined with a
negative ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some other companies you may want to consider as our
model shows that they have the right combination of elements,
i.e., a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or
) has an Earnings ESP of +0.89% and holds a Zacks Rank #2 (Buy).
Allergan will report first quarter earnings on May 7.
) has an Earnings ESP of +5.06% and holds a Zacks Rank #1 (Strong
Buy). Mallinckrodt will report second quarter fiscal 2014
earnings on May 8.
Perrigo Company plc
) has an Earnings ESP of +0.65% and holds a Zacks Rank #2.
Perrigo will report third quarter fiscal 2014 earnings on May
ALLERGAN INC (AGN): Free Stock Analysis
MALLINCKRODT PL (MNK): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
PERRIGO CO PLC (PRGO): Free Stock Analysis
To read this article on Zacks.com click here.